What SCHOTT Pharma does

SCHOTT Pharma AG & Co. KGaA is a Mainz-headquartered, Frankfurt-listed pharmaceutical primary packaging manufacturer tracing its glass-science roots to 1884. The company produces Type I borosilicate glass (FIOLAX®) and pharmaceutical-grade polymer containers for injectable drugs across syringes, cartridges, vials, and ampoules, organized under brands including syriQ®, syriQ BioPure®, SCHOTT TOPPAC®, cartriQ®, adaptiQ®, and the modular EVERIC® family (pure, care, freeze, strong & smooth, smart, plus, lyo, amber). Proprietary technologies such as FIOLAX® CHR tubing, the DC (delamination controlled) forming process, PICVD interior coating, and a broad portfolio of ready-to-use container formats underpin its positioning in biologics, vaccines, mRNA, GLP-1 therapies, and antibody-drug conjugates.

The business model is B2B enterprise selling on multi-year, quote-based contracts directly to pharmaceutical companies, biotechs, and CDMOs, supplemented by analytical, fill-and-finish, and regulatory services and complemented by trade-show engagement at events such as CPHI Frankfurt and Pharmapack Paris. FY2025 revenue was EUR 986.2M with a 28.4% EBITDA margin; H1 2026 revenue of EUR 488.1M places the run-rate near EUR 1B, while high-value solutions have grown to 56% of revenue against a mid-term target of >60%. Manufacturing spans Germany, Hungary, Switzerland, Serbia, the United States (Lebanon and Duryea, Pennsylvania), Mexico, Brazil, China, Argentina, Colombia, France, and Indonesia, with major capacity expansions underway in Serbia, Hungary, Switzerland, Mexico, and Lebanon (the latter a $60M+ BARDA-supported build-out inaugurated in June 2026 that triples U.S. capacity).

Customers choose SCHOTT Pharma for regulatory-validated, switching-cost-heavy packaging solutions embedded in their drug filings, with key differentiators including the EVERIC® lyo & amber vial (first to meet light-transmission rules in EU, U.S., and Japan simultaneously) and pre-validated integrations with SHL Medical, Ypsomed, and Datwyler delivery devices. Strategic priorities articulated by management include a 6-8% revenue CAGR for FY2027-2029, EBITDA margin expansion toward 30%, and decarbonization via FIOLAX® Pro electrified glass-melting, alongside a CEO succession triggered by a long-tenured leader's retirement.

Name

SCHOTT Pharma

Legal name

SCHOTT Pharma AG & Co. KGaA

Website

https://schott-pharma.com

Company type

Public

Founded year

1884

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

SCHOTT Pharma is a German, Frankfurt-listed pharmaceutical primary packaging manufacturer producing Type I borosilicate glass and polymer vials, syringes, cartridges, and ampoules. It serves global pharmaceutical companies, biotechs, and CDMOs across biologics, vaccines, mRNA, GLP-1, and ADC therapies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Primary Packaging

NAICS

Glass Container Manufacturing (327213), Other Pressed and Blown Glass and Glassware Manufacturing (327212), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Glass Containers (3221), Glass & Glassware, Pressed Or Blown (3220), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes) (IMALAEAB)

akta.pro secondary industries

Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges) (IMALAIAE), Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers) (IMALAIAB), Medical & Pharmaceutical Thermoformed Packaging (IMANAHAB)

Keywords

• Pharmaceutical primary packaging
• Prefillable syringes
• Glass vials cartridges
• Injectable drug containment
• Biologics packaging solutions

Headquarters

HQ city

Mainz

HQ country

Germany

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Drug Containment Solutions: Primary revenue driver comprising prefillable syringes, vials, cartridges, and ampoules. Segment generated EUR 286.4 million in H1 revenue (up 8.3%) and EUR 137.2 million in Q1 2026 (up 9.4%), driven by strong demand for sterile cartridges and specialty vials.
2. Drug Delivery Systems: Complete drug delivery systems and related services. Segment remained stable at EUR 103.1 million in Q1 2026. Faces headwinds from weak polymer syringe demand and revised glass syringe demand from a key customer.
3. Analytical and Regulatory Services: Services including delamination studies, particle analysis, extractables and leachables studies, compendial testing, mechanical stability testing, packaging component characterization, functional testing, container closure integrity testing, regulatory support, and fill-and-finish optimization.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

SCHOTT Pharma manufactures and supplies primary packaging and drug delivery solutions for injectable pharmaceuticals, including prefillable glass and polymer syringes, glass cartridges, vials, and ampoules made from Type I borosilicate glass (FIOLAX) and high-grade pharmaceutical polymers. The company also provides integrated analytical, regulatory, and fill-and-finish support services for pharmaceutical and biotech customers.

Product overview

SCHOTT Pharma provides an extensive portfolio of drug containment and drug delivery solutions for injectable drugs, ranging from prefillable syringes and cartridges to vials and ampoules—all made using Type I Borosilicate Glass and high-grade pharmaceutical polymer. The product portfolio is organized into several key families: the syriQ® and SCHOTT TOPPAC® syringe lines (glass and polymer prefillable syringes for vaccines, biologics, and specialized applications); cartriQ® and SCHOTT TOPPAC® cartridge products (glass and polymer cartridges including double chamber, break-resistant, and large-volume variants); the EVERIC® vial family including pure, care, freeze, strong & smooth, smart, plus, lyo, and amber variants addressing different drug stability and application needs, plus adaptiQ® ready-to-use vials and Core Vials; and ampoule products including easyOPC and Anti-Counterfeiting variants. Beyond products, SCHOTT Pharma offers comprehensive services spanning drug containment development, pharmaceutical analytics (delamination, particle, extractables/leachables testing), fill-and-finish support, regulatory services (DMF, LoA, MDR dossiers), and sustainability assessment. FIOLAX® Pro represents upcoming electrified glass fusion technology. The company operates as a vertically integrated solution provider, combining manufactured containers with analytical, development, and regulatory services to support pharmaceutical companies from clinical trials through commercial production.

Differentiator

Problem solved

Functional benefit

Brands

• syriQ: Ready-to-use prefillable glass syringes for vaccines
• syriQ BioPure
• SCHOTT TOPPAC
• cartriQ
• adaptiQ
• EVERIC
• FIOLAX
• Pharmaversity

Products and services

• syriQ Ready-to-use prefillable glass syringes designed for safe and reliable vaccine storage and injection, made from Type I borosilicate glass.
• syriQ BioPure Ready-to-use prefillable glass syringes designed for biologics with enhanced biocompatibility and drug stability.
• syriQ BioPure silicone-free Ready-to-use prefillable and silicone-free glass syringes for biologics requiring silicone-free processing.
• SCHOTT TOPPAC Ready-to-use prefillable polymer syringes offering alternatives to glass for specific drug formulations.
• SCHOTT TOPPAC cosmetic Ready-to-use prefillable polymer syringes designed for aesthetic treatments.
• SCHOTT TOPPAC freeze Ready-to-use prefillable polymer syringes designed for deep-cold applications.
• SCHOTT TOPPAC infuse Ready-to-use prefillable polymer syringes designed for infusion therapy.
• syriQ BioPure 5.5 mL Prefillable Staked-Needle Glass Syringe First 5.5 mL prefillable staked-needle glass syringe for large-volume biologic therapies, integrating with Ypsomed YpsoMate and Datwyler plunger systems with ultra-low tungsten levels.
• cartriQ Ready-to-use pharmaceutical glass cartridges for peptide and protein-based injectables.
• cartriQ BioPure Ready-to-use pharmaceutical glass cartridges designed for biologics with enhanced drug compatibility.
• cartriQ Large Volume Ready-to-use pharmaceutical glass cartridges for large-volume injectables.
• SCHOTT TOPPAC cartridge Ready-to-use polymer cartridge for highly sensitive biologics, verified compatible with SHL Medical's large-volume autoinjectors.
• Cartridges Double Chamber (DC) Pharmaceutical glass cartridges for safe and convenient handling of lyophilized drugs.
• Cartridges Break Resistant (BR) Pharmaceutical glass cartridges designed for demanding conditions with enhanced durability.
• adaptiQ Ready-to-use pharmaceutical glass vials for injectables, pre-sterilized to reduce contamination risks.
• EVERIC pure Pharmaceutical glass vials with homogeneous inner surface for unmatched drug stability, made from improved Type I borosilicate glass (FIOLAX CHR).
• EVERIC freeze Pharmaceutical glass vials designed for deep-cold applications including mRNA and gene-therapy products requiring ultra-low temperature storage.
• EVERIC lyo & amber Amber-colored specialty vials with hydrophobic inner coating for light-sensitive lyophilized antibody-drug conjugates used in targeted cancer therapies.
• Ampoules easyOPC Pharmaceutical glass ampoules for safe and easy ampoule opening with enhanced break-off system.
• Drug Containment Solutions Services Services including feasibility studies, prototyping, design and development, and DHF documentation for drug containment systems.
• Pharma Analytics Services Comprehensive analytical testing including delamination studies, particle analysis, extractables and leachables studies, compendial testing, mechanical stability testing, packaging component characterization, functional testing, and container closure integrity testing.
• Fill-and-Finish Services Services for filling line compatibility verification and filling line efficiency optimization.
• Regulatory Services Regulatory support including Letter of Authorization (LoA), Drug Master Files (DMF), national product registration, pharmaceutical packaging dossiers, and Medical Device Registration (MDR) dossiers.
• FIOLAX Pro Next-generation glass fusion technology using electrified melting process, expected to reduce carbon footprint by approximately 50% for glass vials, ampoules, and cartridges.

Quantifiable outcome

• 98% reduction in cosmetic defects with EVERIC® smooth vials compared to uncoated vials
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature8 records

Partnerships

Six partnerships are on record, tiered core and minor.

• SHL MedicalcoreTechnology or Integration · 14 January 2026SCHOTT Pharma's TOPPAC® polymer cartridge became the first sterile polymer cartridge platform verified for compatibility with SHL Medical's Maggie® large-volume autoinjector. Joint compatibility studies confirmed full system compatibility across 3ml and 5ml cartridge configurations, enabling pre-validated solutions for large-volume medication self-administration at home. Companies expanding collaboration to assess compatibility with pen systems and additional medical devices.
• YpsomedcoreTechnology or IntegrationSCHOTT Pharma's 5.5 mL prefillable staked-needle glass syringe is compatible with Ypsomed's YpsoMate 5.5 mL autoinjector. The integration supports the shift from intravenous to subcutaneous home administration of biologics for immunology, oncology, and CNS disorders.
• Alliance to ZerocoreStrategic or Co-development PartnerSCHOTT Pharma is a founding member of the Alliance to Zero, an industry association of companies striving to decarbonize the injection device value chain. The alliance enables co-innovation with suppliers, partners, and customers for new concepts, services, and products.
• TakedaminorStrategic or Co-development PartnerSCHOTT Pharma collaborated with Takeda to demonstrate closed-loop recycling for pharmaceutical packaging without compromising patient safety.
• CorplexminorStrategic or Co-development PartnerSCHOTT Pharma partnered with Corplex to develop and demonstrate closed-loop recycling systems for pharmaceutical packaging trays, achieving 70% recycled content with approximately 50% CO2 footprint reduction.
• Körber PharmaminorStrategic or Co-development PartnerSCHOTT Pharma collaborated with Körber Pharma and Schreiner MediPharm to transfer blister packaging functionality to syringe, label, and carton, reducing material usage and CO2 emissions.

Scale indicators10 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• Nipro Corporation: Japanese manufacturer of medical devices and pharmaceutical glass packaging, including vials, ampoules, syringes and prefillable systems. Comparable in glass primary packaging breadth and biologics containment, with strong APAC footprint.
• West Pharmaceutical Services: US-listed supplier of primary packaging (stoppers, seals, syringes, cartridges) and delivery devices for injectable drugs. Direct competitor in elastomeric closures and integrated containment/delivery solutions for biologics and advanced therapies.
• SGD Pharma: French specialist in molded and tubular pharmaceutical glass packaging (vials, bottles, droppers) serving global pharma customers. Direct competitor in primary glass containment, particularly for injectables and sterile drugs.
• Stevanato Group: Italian producer of pharmaceutical glass containers (vials, syringes, cartridges) and drug delivery systems, including integrated solutions for biologics. Direct competitor in glass primary packaging and prefillable syringe platforms.
• AptarGroup: US-listed supplier of drug delivery systems and dispensing solutions including prefilled syringe components, autoinjector and nasal interfaces. Comparable in delivery-device integration on top of containment, and partner/competitor at the drug-delivery boundary.
• Gerresheimer: German-headquartered manufacturer of glass and plastic primary packaging for pharmaceuticals, with a directly overlapping product portfolio of vials, syringes, ampoules and cartridges serving the same pharma and biotech customers. Closest direct competitor to SCHOTT Pharma's core glass containment business.

Broad incumbents

• Terumo Corporation: Japanese medtech player with a Pharmaceutical Solutions Division producing prefillable syringes, needles and drug delivery devices for biologics. Comparable in prefillable syringe systems but operates broader hospital and blood-bag businesses.
• Becton, Dickinson and Company (BD): Diversified global medical-technology company whose BDX Medical segment includes prefillable syringe systems, injection devices and pharmaceutical services. Overlaps with SCHOTT Pharma in syringes and drug delivery but operates across a much wider portfolio.

Regional players

• DWK Life Sciences: Manufacturer of specialty glass containers and laboratory glassware including pharmaceutical primary packaging. Comparable in glass container production but with primary emphasis on laboratory and specialty industrial applications rather than large-scale injectable containment.

Emerging players

• Corning Pharmaceutical Technologies: Business unit of Corning leveraging proprietary glass-ceramic (Valor Glass) and other advanced glass technologies for pharmaceutical vials and drug containment. Emerging alternative in high-end injectable packaging competing with SCHOTT's EVERIC and FIOLAX franchises.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/schott-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SCHOTT Pharma